Tazasubrate

This classification denotes an anti-lipidemic agent with the molecular formula C18H17NO3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6SGF1AP698, chemically known as benzeneacetic acid, alpha-(((6-ethoxy-2-benzothiazolyl)thio)methyl)-, (+-)- but generally known as tazasubrate, which bears US NIH Compound Identifier 174749. European Medicines Agency schedules Tazasubrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10845MIG. The term TAZASUBRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). TAZASUBRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule tazasubrate under HS 29341000 and SITC 51579. As of Q4 2014, TAZASUBRATE remains the US FDA Preferred Term for this commodity. Tazasubrate bears US NLM identifiers UMLS ID C0144579 and NCI Concept Code C72999. SMILES: S(C(c1ccccc1)(C)C(=O)O)c1sc2c(n1)ccc(OCC)c2.